Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy
Phase 3
Completed
NCT05536297
| Condition | Geographic Atrophy, Age-Related Macular Degeneration |
|---|
| Phase | Phase 3 |
|---|
| Sponsor | Astellas Pharma Global Development, Inc. |
|---|
| Status | Completed |
|---|
| Enrollment | 278 participants |
|---|
| Interventions | avacincaptad pegol |
|---|
| Start date | Sep 26, 2022 |
|---|
| Completion date | Apr 10, 2025 |
|---|
| Results posted | Apr 14, 2026 |
|---|
Summary
The purpose of this study is to assess long-term safety of avacincaptad pegol intravitreal administration for patients with geographic atrophy (GA) who completed Study ISEE2008 (GATHER2) through the Month 23 visit on study treatment (either avacincaptad pegol or Sham).
Number of Participants With Adverse Events (AEs)
Up to 18 months · Participants
| ACP EM to ACP EM | 50 Participants |
|---|
| ACP EM/EOM to ACP EM | 49 Participants |
|---|
| Sham to ACP EM | 129 Participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.